Navigation Links
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014
Date:11/7/2013

$  40,628Services 

47,07342,120Total net revenue 

76,64182,748Cost of revenue:Cost of products 

18,60124,009Cost of services 

31,56235,063Total cost of revenue 

50,16359,072Gross profit 

26,47823,676Operating expenses:Selling and marketing 

14,45412,889Research and development 

12,95018,574General and administrative 

11,36012,842Total operating expenses 

38,76444,305Loss from operations

(12,286)(20,629)Other expense, net

(2,460)(704)Loss before provision for income taxes

(14,746)(21,333)Provision for income taxes

787597Loss from continuing operations

(15,533)(21,930)Loss from discontinued operations attributable to stockholders

-(2,200)Net loss attributable to stockholders

$(15,533)$(24,130)Loss per share attributable to stockholdersBasic and diluted - continuing operations

$
(0.21)$
(0.31)Basic and diluted - discontinued operations

$
-$
(0.03)Basic and diluted - net loss

$
(0.21)$
(0.34)Weighted average common shares used in computing loss per shareBasic and diluted

74,70071,995  Accuray Incorporated  Consolidated Balance Sheets  (in thousands)  (Unaudited)  September 30,  June 30, 20132013 Assets  Current assets:  Cash, cash equivalents and investments 

$
,595

$
74,397 Restricted cash 

2,783

2,728 Accounts receivable, net of allowance for doubtful accounts 

60,136

55,458 Inventories 

87,989

81,592 Prepaid expenses and other current assets 

13,083

12,595 Deferred cost of revenue 

8,658

9,165Total current assets 

334,244

335,935
'/>"/>

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
2. Accuray Announces First CyberKnife System in South America
3. Accuray Surpasses 600 Installations Globally
4. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
5. Omeros Corporation Reports Third Quarter 2013 Financial Results
6. Global Positron Emission Tomography Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
7. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
8. Global Biophotonics Market & OSS BSS Industry 2012-2016 Reports
9. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Neurocrine Biosciences Reports Third Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... Satisfies initial listing requirements with NASDAQ; Stock ... which extends cash runway while focusing ... Aug. 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly ... "Company") announced that the Company has completed ...
... Management and Supports Best-Of-Breed, Clinical Environments - Without ... ... Software Upgrades, OAKLAND, Calif., Aug. 21 ... and information,systems, and Epiphany Cardiography Products, introduce CardioECG 3.2,multi-modality, multi-vendor, ...
... Netherlands, August 21 Hoya,Corporation,s Vision Care Division, a ... today that it acquired Dioptra CZ a.s., one of,the ... Dioptra has a long and rich tradition in ... and Dioptra have worked together under an,exclusive arrangement since ...
Cached Biology Technology:Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution 2Hoya Vision Care Expands in Czech Republic 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... has been implicated in heart disease, weight gain, and diabetes, ... a source of chronic stress, present a challenge even for ... some species somehow manage to survive, and even thrive, in ... Yuri Springer in the November issue of the American ...
... Medical Center in New York have confirmed that Homo ... a descendant of healthy humans dwarfed by disease. Using ... researchers determined the "hobbit" to be a distinct species and ... of the study appear in the December issue of ...
... that can boost fuel efficiency without sacrificing safety and durability ... tires could help add an extra mile or two per ... the cover story of the current issue of Chemical & ... Editor Alexander Tullo explains that rolling resistance the friction ...
Cached Biology News:The benefits of stress ... in plants 2'Hobbits' are a new human species -- according to the statistical analysis of fossils 2